Stockscreener 앱 받기
17.43
0.21%
-0.0337
전일 마감가:
$17.46
열려 있는:
$17.53
하루 거래량:
3.51M
Relative Volume:
0.38
시가총액:
$20.01B
수익:
$14.57B
순이익/손실:
$-296.50M
주가수익비율:
-67.28
EPS:
-0.259
순현금흐름:
$1.64B
1주 성능:
-2.28%
1개월 성능:
+1.95%
6개월 성능:
+29.64%
1년 성능:
+72.34%
1일 변동 폭
$17.34
$17.65
1주일 범위
$17.34
$18.43
52주 변동 폭
$9.69
$18.43
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
17.42 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
17.81 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.59 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.78 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.73 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
544.58 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 업그레이드 | UBS | Neutral → Buy |
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - Zacks Investment Research
Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says - Moomoo
Net income before discontinued operations of Viatris, Inc. – HAN:VIA - TradingView
Viatris named to Forbes' World's Best Employers list for sixth year, highlighting strong workplace culture. - Pluang
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year - PR Newswire
Viatris stock hits 52-week high at 18.4 USD By Investing.com - Investing.com Australia
Viatris stock hits 52-week high at 18.4 USD - Investing.com
Viatris Inc Agencies, 2022 - OpenSecrets
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune
Viatris Inc Agencies, 2026 - OpenSecrets
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Viatris sues Novo Nordisk, seeks to market generic Wegovy - Seeking Alpha
Viatris sues Novo Nordisk over generic Wegovy patent dispute - Yahoo Finance
Viatris sues Novo Nordisk over generic Wegovy patent dispute By Investing.com - Investing.com Canada
Mylan asks US court to clear Wegovy generic from Novo patent claims - reuters.com
Trump seeks to produce more generic drugs in the US - Seeking Alpha
Is Viatris Stock Outperforming the S&P 500? - Yahoo Finance
How Viatris Inc. (VTRS) Affects Rotational Strategy Timing - Stock Traders Daily
Viatris (VTRS) Q4 2025 Earnings Call Transcript - fortune.com
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Oppenheimer Initiates Viatris at Outperform With $25 Price Target - marketscreener.com
Oppenheimer initiates Viatris stock with outperform rating - Investing.com
Oppenheimer initiates Viatris stock with outperform rating By Investing.com - Investing.com Nigeria
Viatris Inc. (VTRS) Stock Analysis: Exploring A 10.78% Upside With Strategic Collaborations - DirectorsTalk Interviews
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? - Yahoo Finance
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Piper Sandler raises Viatris stock price target on patch growth - Investing.com
Viatris receives Japan approval for sleep disorder drug Wakix - Investing.com
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome - PR Newswire
Piper Sandler Adjusts Price Target on Viatris to $13 From $12, Keeps Neutral Rating - Yahoo Finance
Viatris, Long Chau launch lipid disorder management campaign - VnExpress International
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards? - Eastern Progress
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha
VTRS - Finviz
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan
Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Viatris Inc. (VTRS) Stock Analysis: Exploring Its 13% Upside Potential And Dividend Appeal - DirectorsTalk Interviews
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough? - Yahoo Finance
Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overv - GuruFocus
Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score - GuruFocus
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
비아트리스 주식 (VTRS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Campbell Paul | See Remarks |
Jun 25 '26 |
Sale |
16.17 |
50,076 |
809,784 |
316,212 |
3.91%
1.57%
자본화:
|
볼륨(24시간):